Literature DB >> 30859234

[Chemohormonal therapy for metastatic prostate cancer : Taxane-based approaches].

Annabel Spek1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30859234     DOI： 10.1007/s00120-019-0899-0

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  7 in total

Review 1.  Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Marcello Tucci; Valentina Bertaglia; Francesca Vignani; Consuelo Buttigliero; Cristian Fiori; Francesco Porpiglia; Giorgio Vittorio Scagliotti; Massimo Di Maio
Journal:  Eur Urol       Date:  2015-09-28       Impact factor: 20.096

2.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

Review 3.  Characterising the castration-resistant prostate cancer population: a systematic review.

Authors:  M Kirby; C Hirst; E D Crawford
Journal:  Int J Clin Pract       Date:  2011-11       Impact factor: 2.503

4.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

Review 5.  Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Tobias Engel Ayer Botrel; Otávio Clark; Antônio Carlos Lima Pompeo; Francisco Flávio Horta Bretas; Marcus Vinicius Sadi; Ubirajara Ferreira; Rodolfo Borges Dos Reis
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

Review 6.  Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Authors:  Claire L Vale; Sarah Burdett; Larysa H M Rydzewska; Laurence Albiges; Noel W Clarke; David Fisher; Karim Fizazi; Gwenaelle Gravis; Nicholas D James; Malcolm D Mason; Mahesh K B Parmar; Christopher J Sweeney; Matthew R Sydes; Bertrand Tombal; Jayne F Tierney
Journal:  Lancet Oncol       Date:  2015-12-21       Impact factor: 41.316

7.  Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

Authors:  Nicholas David James; Melissa R Spears; Noel W Clarke; David P Dearnaley; Johann S De Bono; Joanna Gale; John Hetherington; Peter J Hoskin; Robert J Jones; Robert Laing; Jason F Lester; Duncan McLaren; Christopher C Parker; Mahesh K B Parmar; Alastair W S Ritchie; J Martin Russell; Räto T Strebel; George N Thalmann; Malcolm D Mason; Matthew R Sydes
Journal:  Eur Urol       Date:  2014-10-06       Impact factor: 20.096
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.